NSE · Healthcare · Drug Manufacturers - Specialty & Generic
EPS came in at 0.38 against a street estimate of 0.70 — a miss of 45.7%.
| Document | Date |
|---|---|
| Investor presentation · Q1 FY27 THEMIS MEDICARE LIMITED – Q1 FY27 INVESTOR SUMMARY HEADLINE NUMBERS • Consolidated Revenue Q1 FY27: ₹86.96 crore (down 10.9% YoY from ₹97.58 crore i | 2026-08-13 |
| Quarterly results · Q1 FY27 THEMIS MEDICARE LIMITED – BOARD MEETING SUMMARY (13 AUGUST 2026) HEADLINE NUMBERS • Quarter ended 30 June 2026: Un-audited standalone and consolidat | 2026-08-13 |
| Investor presentation · Q4 FY26 THEMIS MEDICARE LIMITED – Q4 & FY26 INVESTOR SUMMARY HEADLINE NUMBERS • FY26 Consolidated Revenue: ₹342.2 crore (down 15.6% YoY from ₹405.5 crore in | 2026-05-28 |
| Quarterly results · Q4 FY26 THEMIS MEDICARE LIMITED – DOCUMENT SUMMARY HEADLINE NUMBERS • FY 2025-26 Revenue from Operations (Net): Rs. 34,223.55 lakhs, down 15.6% from Rs. 40, | 2026-05-28 |
| Quarterly results · Q3 FY26 THEMIS MEDICARE LIMITED – DOCUMENT SUMMARY HEADLINE NUMBERS • Q3 FY2025-26 Standalone Revenue: Rs 9,013.32 lakhs (vs Rs 9,380.63 lakhs in Q3 FY2024- | 2026-02-13 |
| Investor presentation THEMIS MEDICARE LIMITED - Q3 & 9M FY26 INVESTOR SUMMARY HEADLINE NUMBERS • Q3 FY26 Revenue: ₹90.13 crore (down 3.9% YoY from ₹93.81 crore in Q3 FY25 | 2026-02-13 |
| Investor presentation · Q2 FY26 THEMIS MEDICARE LIMITED – Q2 & H1 FY26 SUMMARY HEADLINE NUMBERS • Q2 FY26 Revenue: ₹78 crore (down 33.3% YoY from ₹117 crore in Q2 FY25) • Q2 FY26 P | 2025-11-13 |
| Quarterly results · Q2 FY26 THEMIS MEDICARE LIMITED – FINANCIAL SUMMARY HEADLINE NUMBERS • Q2 FY2025-26 Revenue (Standalone): INR 7,799.41 lakhs (down 33% YoY from INR 11,700.9 | 2025-11-13 |
Readable in the app.
| Action | Detail | Date |
|---|---|---|
| Dividend | ₹0.50 / share ex-date Sep 4, 2025 · record Sep 5, 2025 | 2025-09-04 |
Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Themis Medicare Limited — free to start.
Google PlayApp StoreData updated 2026-09-18.